Sugi Predict

Sugi Predict / Compounds / SCHEMBL603077

SCHEMBL603077

SCHEMBL603077

N#Cc1cc(F)c(C=O)c(F)c1

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ EPAS1 Q99814 1/20 0.36
▸ VCAM1 P19320 2/20 0.34
▸ TTR P02766 2/20 0.32
▸ ALB P02768 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ TRPV4 Q9HBA0 1/20 0.32
▸ HTR7 P34969 1/20 0.32
▸ EGLN2 Q96KS0 2/20 0.32
▸ KIF11 P52732 1/20 0.32
▸ P4HB P07237 2/20 0.31
▸ RAD51 Q06609 1/20 0.31
▸ GPR35 Q9HC97 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15321643 0.86 EPAS1 (0.38) EPAS1TTRALBMEN1KMT2A
SCHEMBL18939009 0.86 GRM5 (0.35) EPAS1VCAM1MEN1KMT2A
SCHEMBL31254869 0.86 GRM5 (0.35) EPAS1VCAM1MEN1KMT2A
SCHEMBL15321953 0.79 EPAS1 (0.34) EPAS1EGLN2
SCHEMBL16812299 0.77 KIF11 (0.35) VCAM1TTRALBMEN1KMT2A
SCHEMBL20456765 0.77 CA12 (0.31) MEN1KMT2A
SCHEMBL4146478 0.77 ERN1 (0.34) VCAM1HTR7
SCHEMBL6898133 0.74 VCAM1 (0.40) EPAS1VCAM1TTRALBMEN1
SCHEMBL13179007 0.74 ERN1 (0.30) —
SCHEMBL411743 0.74 ERN1 (0.58) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114984928-A Modified porous cyclodextrin polymer material and preparation method and application thereof 中南大学 2022-09-02 — — CN claimed
WO-2026107227-A1 COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2026-05-21 — — WO disclosed
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 — — EP disclosed
US-20250230137-A1 P300/CBP HAT INHIBITORS CONSTELLATION PHARMACEUTICALS INC (US) 2025-07-17 — — US disclosed
WO-2025129135-A2 COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-06-19 — — WO disclosed
US-20250026742-A1 COMPOUND AS ATR KINASE INHIBITOR SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) 2025-01-23 — — US disclosed
CN-115703768-B Compounds useful as inhibitors of ATR kinase 苏州爱科百发生物医药技术有限公司 2024-12-17 — — CN disclosed
WO-2024233665-A1 COMPOUNDS AND THEIR USE AGAINST CANCER TANGO THERAPEUTICS, INC. (US) 2024-11-14 — — WO disclosed
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-11-07 — — US disclosed
WO-2024199255-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 — — WO disclosed
US-20090286800-A1 Glucokinase Activators TAKEDA SAN DIEGO, INC. (US) 2009-11-19 — — US disclosed
EP-2102167-A2 SUBSTITUTED ARYLPYRAZOLES Pfizer Limited (GB) 2009-09-23 — — EP disclosed
WO-2008141249-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2008-11-20 — — WO disclosed
US-20080176865-A1 SUBSTITUTED ARYLPYRAZOLES PFIZER LIMITED (GB) 2008-07-24 — — US disclosed
WO-2008072053-A2 SUBSTITUTED ARYLPYRAZOLES PFIZER LIMITED (GB) 2008-06-19 — — WO disclosed
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 — — EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 — — US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 — — EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 — — US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026742-A1 COMPOUND AS ATR KINASE INHIBITOR ATR, CHEK2, CHEK1 EPAS1 963/4885VCAM1 4191/4885TTR 2929/4885
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 EPAS1 4083/4885VCAM1 1341/4885TTR 4420/4885
US-20080176865-A1 SUBSTITUTED ARYLPYRAZOLES CYP3A4, CYP3A43, CYP4B1 EPAS1 3653/4885VCAM1 4482/4885TTR 1275/4885
US-20090286800-A1 Glucokinase Activators GCK, GCKR, GALK1 EPAS1 1218/4885VCAM1 4052/4885TTR 2401/4885
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 PRMT5, PRMT6, PRMT1 EPAS1 1854/4885VCAM1 3677/4885TTR 4616/4885
US-20250230137-A1 P300/CBP HAT INHIBITORS EP300, HDAC1, KAT2A EPAS1 407/4885VCAM1 2231/4885TTR 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.